Esperion Therapeutics Inc (Esperion) is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate, Bempedoic acid is an ATP-citrate lyase inhibitor is in the clinical development phase that reduces elevated LDL-C levels in patients with hypercholesterolemia. The company also provides the development of bempedoic acid in a fixed-dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.
Esperion Therapeutics Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline: | NEXLIZET |
Ezetimibe | NEXLETOL |
Bempedoic Acid |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In March, the company secured approval from the United States Food and Drug Administration for broad new label expansions for NEXLETOL Tablets and NEXLIZET Tablets. |
2023 | Contracts/Agreements | In April, the company entered into an agreement with Currax Pharmaceuticals to co-promote NEXLETOL tablets and NEXLIZET tablets. |
2023 | Contracts/Agreements | In March, the company entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock. |
Competitor Comparison
Key Parameters | Esperion Therapeutics Inc | Cyclacel Pharmaceuticals Inc | BrainStorm Cell Therapeutics Inc | Lisata Therapeutics Inc | Stemline Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Vero Beach | Berkeley Heights | New York | Basking Ridge | New York |
State/Province | Florida | New Jersey | New York | New Jersey | New York |
No. of Employees | 240 | 12 | 29 | 25 | - |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
J. Martin Carroll | Chairman | Executive Board | 2022 | 73 |
Sheldon Koenig | Director; Chief Executive Officer; President | Executive Board | 2021 | 57 |
Ben Halladay | Chief Financial Officer | Senior Management | 2022 | - |
Betty Jean Swartz | Chief Strategy Officer | Senior Management | 2022 | - |
JoAnne Micale Foody | Chief Medical Officer | Senior Management | 2021 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer